Client News

Masters Speciality Pharma Announces Launch of Neuropad® in Brazil for Detection of Diabetic Foot Syndrome

Masters Speciality Pharma, a UK-headquartered pharmaceutical company specialising in the global distribution of high-quality, life-changing medicines, today announces the recent launch in Brazil of Neuropad®, a rapid and reliable screening … Continue reading “Masters Speciality Pharma Announces Launch of Neuropad® in Brazil for Detection of Diabetic Foot Syndrome”

By Optimum

Neuraxpharm enters booming CBD market with the acquisition of leading Switzerland-based S.T.U GMBH

-Neuraxpharm establishes Swiss footprint with acquisition of leading cannabidiol company -S.T.U. GmbH is the owner of market leading brand Hemplix™ October 29, 2019 Neuraxpharm Group (Neuraxpharm), a leading European specialty … Continue reading “Neuraxpharm enters booming CBD market with the acquisition of leading Switzerland-based S.T.U GMBH”

By Optimum

Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD

Results to Inform Development Plan and Dose Selection for Phase 3 LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company … Continue reading “Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD”

By Optimum

IXICO Company reports fast tracked achievement of initial year positive EBITDA, 40% revenue growth and strong cash position

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, is pleased to announce a trading update for the year ended 30 September 2019.  IXICO is expecting … Continue reading “IXICO Company reports fast tracked achievement of initial year positive EBITDA, 40% revenue growth and strong cash position”

By Optimum

ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology

ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda Pharmaceutical Company Limited … Continue reading “ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology”

By Optimum

GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

• Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. • The two companies will leverage their combined scientific, commercial and market access expertise to … Continue reading “GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer”

By Optimum

Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon

Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company’s lead compound Nefecon, … Continue reading “Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon”

By Optimum

OCTIMET expands ongoing proof of concept study to evaluate the combination of highly selective MET Kinase Inhibitor OMO-1 with EGFR TKIs

OMO-1 has potential to treat cancer as a monotherapy and in combination with EGFR TKIs for patients becoming resistant to or progressing on treatment Beerse, Belgium, 25 September 2019 – … Continue reading “OCTIMET expands ongoing proof of concept study to evaluate the combination of highly selective MET Kinase Inhibitor OMO-1 with EGFR TKIs”

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH